School of Medicine
Showing 101-131 of 131 Results
-
Steven Sanislo, MD
Clinical Professor, Ophthalmology
BioDr Sanislo has over 20 years of experience in clinical and surgical practice in retinal and vitreoretinal diseases. He is the senior vitreoretinal surgeon at Stanford and maintains a large clinical practice as well as teaching ophthalmology residents and retina fellows. He also participates in clincal reasearch for varying retinal conditions. Dr. Sanislo recieved ophthalmology training as a resident here at Stanford, and recieved vitreoretinal training as a fellow at the Cleveland Clinic Foundation.
Research interests include treatment of age-related macular degeneration, diabetic retinopathy and other retinal diseases.
Dr. Sanislo has extensive clinical and surgical experience in the following diseases:
- Age-related macular degeneration
- Posterior uveitis / infectious and inflammatory disease of the posterior segment
- Diabetic retinopathy
- Myopic degeneration / pathologic myopia
- Macular pucker / epiretinal membranes
- Macular hole
- Repair of simple and complex retinal detachments
- Macular edema
- Retinal vascular occlusion -
Yasir Sepah
Assistant Professor (Research) of Ophthalmology
Current Research and Scholarly InterestsYasir's primary focus is on early identification of ocular diseases and objective assessment of response to therapy via biomarker (imaging and molecular) discovery and endpoints development for clinical trials. His lab is also developing and implementing protocols and methods to make decentralized clinical trials in ophthalmology viable.
Yasir is also engaged in developing low-tech, low cost and less intelligent solutions in order to improve patient's access to care. -
Ann Shue, MD
Clinical Assistant Professor, Ophthalmology
Clinical Assistant Professor (By courtesy), PediatricsBio**Dr. Shue is taking new patients for glaucoma, cataracts, and adult strabismus.**
Ann Shue, MD, is a Clinical Assistant Professor of Ophthalmology at Stanford University School of Medicine, where she specializes in glaucoma, pediatric ophthalmology, and adult strabismus, a unique combination of subspecializations practiced by few surgeons worldwide. She is a board-certified ophthalmologist who completed fellowships in glaucoma at Yale University and pediatric ophthalmology and adult strabismus at Duke University. She practices at the Stanford Byers Eye Institute and the Lucile Packard Children's Hospital.
Dr. Shue loves seeing patients of all ages with eye problems big or small, including glaucoma due to any reason, glaucoma suspicion, family history of glaucoma, cataracts, strabismus (eye misalignment) or double vision from any cause, including after eye surgeries. She completed her ophthalmology residency at the University of Pittsburgh and an internal medicine internship at UCSF Fresno. She holds a medical degree from University of California, Irvine and an undergraduate degree in biology from Yale University.
Dr. Shue is a member of the American Glaucoma Society, the American Association for Pediatric Ophthalmology and Strabismus, and the UK Paediatric Glaucoma Society. She is active in presenting at regional and national conferences. She is the author of several journal articles and recently wrote two textbook chapters on pediatric glaucoma and pediatric glaucoma surgery. -
Ruwan Silva, MD, MPhil
Clinical Assistant Professor, Ophthalmology
Clinical Assistant Professor (By courtesy), NeurosurgeryBioProfessor Ruwan Amila Silva, MD, MPhil is board certified and fellowship trained vitreoretinal surgeon in the department of ophthalmology at Stanford University Medical Center. He received his BA in Neurobiology from Harvard University graduating Magna cum laude with Highest Honors. He then received his Masters of Philosophy (MPhil) in Neurobiology from Cambridge University in England. Following this, he received his medical degree from Stanford University’s School of Medicine. Dr. Silva completed his ophthalmology residency at the Bascom Palmer Eye Institute, the top rated eye hospital in the country. While there he was awarded the Heed Fellowship, the most prestigious national award for ophthalmology residents in the country. Dr. Silva returned to Stanford University to complete his vitreoretinal surgery fellowship where he was awarded the Ronald G. Michels Foundation Award, the nation’s highest honor for a retina surgery fellow. During his fellowship at Stanford he was also awarded the prestigious Evangelos S. Gragoudas Award by the Macula Society. Following fellowship, Dr. Silva remained at Stanford University's School of Medicine as an Assistant Professor of Vitreoretinal Surgery in the Department of Ophthalmology. Since 2015, he has been named one of “America’s Top Ophthalmologists” by Consumers’ Research Council of America. He was also selected as a "Top Ophthalmologist" by the International Association of Ophthalmologists.
Dr. Silva's clinical practice focuses mainly on macular degeneration and retinal vascular disease (such as diabetic retinopathy, retinal vein occlusions and central serous retinopathy). Surgically, he specializes in diseases of the vitreous and retina: including repair of retinal detachments, surgery for the macula (such as treatment of epiretinal membranes and macular holes) and correction of dislocated intraocular lenses. His research interests mainly involve developing novel therapies for these diseases (http://med.stanford.edu/artificial-retina.html) and have resulted in over 50 combined peer-reviewed scientific manuscripts, book chapters and national meeting presentations.
Dr. Silva is a member of the American Academy of Ophthalmology, the Association for Research in Vision and Ophthalmology, as well as the American Society of Retina Specialists. He is a Board Certified Diplomate of the American Board of Ophthalmology. -
Kuldev Singh, MD, MPH
Professor of Ophthalmology
Current Research and Scholarly InterestsGlaucoma, clinical epidemiology
-
Stephen Smith, MD
Clinical Assistant Professor, Ophthalmology
Current Research and Scholarly InterestsRESEARCH OVERVIEW
Dr. Smith’s primary professional interest is developing solutions for unmet clinical and surgical vitreoretinal needs. Beginning in medical school, one of his primary focuses has been improving treatment outcomes in patients with retinoblastoma (RB). During his second year in medical school Dr. Smith published a manuscript on a novel technique to reduce the risk of tumor spread following intravitreal drug delivery in patients with RB. His work summarizing published data on tumor spread following intravitreal injection therapy (IVT) for RB has resulted in multiple platform presentations at national and international meetings, including an invited lecture at ARVO 2014. The results of this study influenced the growing trend toward broader acceptance of intravitreal chemotherapy in pediatric patients with treatment-resistant retinoblastoma vitreous seeds. A primary active area of research has included studying and publishing on ocular toxicity that results from the use of intravitreal melphalan and other agents for RB. This work, and subsequent publications from leaders in the field, has led to an increased awareness of ocular toxicity caused by injecting chemotherapeutic agents into the eyes of young children. This highlighted the need for toxicity data on additional chemotherapeutic agents for local delivery. To answer this question, Dr. Smith assembled an excellent group of collaborators and consultants, including internationally known experts at Bascom Palmer, Mayo Clinic, and Emory University. As a resident he secured a highly competitive career starter grant from the Knights Templar Foundation and used that funding and the expertise of his collaborators to carry out preclinical ocular toxicity studies of combination intravitreal chemotherapy for RB. His work in RB has led to a broader recognition of the challenges facing patients with RB who receive IVT and has led to a continued search for optimal local injectable therapies for patients with this disease.
INNOVATION HIGHLIGHTS
In addition to his work in retinoblastoma, Dr. Smith has been actively involved in developing technologies to improve outcomes for patients receiving intravitreal injection therapy (IVT) for macular degeneration, diabetic retinopathy, retinal vein occlusions and more. IVT has become the most common procedure performed by retina specialists in the United States, with an estimated 6 million injections given in the United States alone in 2016. Dr. Smith has co-developed technology that simplifies and streamlines the IVT process, removing barriers to treatment and improving patient outcomes. His work in innovation covers pre-clinical and clinical development work, and has given him expertise in diverse subject areas including fundraising, intellectual property portfolio development, team building, and business administration. He is a co-founder of iRenix Medical, a biotechnology and medical device start-up company committed to improving vision through optimization of the IVT process.
Dr. Smith remains dedicated to helping improve and restore vision and quality of life in patients with vitreoretinal disease. He is currently involved in both medical device and pharmaceutical innovation, and serves as a mentor for the Stanford University Biodesign Innovation Course. -
Gayathri Srinivasan OD, MS
Clinical Associate Professor, Ophthalmology
BioDr. Srinivasan is a Clinical Associate Professor in the Department of Ophthalmology at Stanford University. Her clinical focus is in the management of concussion-related vision disorders. Dr. Srinivasan's research interests are amblyopia, strabismus, and concussion-related vision disorders. She serves as an investigator for ongoing clinical studies in the Vision Development and Oculomotor lab headed by Dr. Tawna Roberts.
-
Creed Stary
Associate Professor of Anesthesiology, Perioperative and Pain Medicine (MSD) and, by courtesy, of Ophthalmology
Current Research and Scholarly InterestsMechanisms promoting neuronal survival following cerebral ischemia-reperfusion injury; utilizing microRNA's to target multiple pathways to promote mitochondrial homeostasis and cell survival; anesthetic neurotoxicity; astrocyte-neuronal interaction
-
Yang Sun, MD, PhD
Professor of Ophthalmology
Current Research and Scholarly InterestsWe are interested in the role of inositol phosphatases in eye development and disease, using both animal models and human disease tissue. We are a translational laboratory seeking to understand the basic function of proteins as well as developing therapeutic strategies for clinical trials.
-
Christopher N. Ta, MD
Professor of Ophthalmology
BioChristopher N. Ta, MD specializes in the diagnosis and medical treatment of cornea diseases. His areas of expertise are in the treatment of ocular infections, inflammation, dry eyes and ocular surface diseases. He has conducted numerous clinical trials toward the prevention and treatment of ocular infections. Dr. Ta also has extensive clinical experience in the treatment of ocular graft-versus host disease following hematopoietic stem cell transplantation.
-
Geoffrey Craig Tabin, MD
Fairweather Foundation Professor
BioDr. Geoff Tabin is Co-Founder and Chairman of the Himalayan Cataract Project and a Professor of Ophthalmology and Global Medicine at Stanford University. He has published more than 45 peer-reviewed articles, two books and a dozen book chapters related to his work in ophthalmology and the developing world.
Dr. Tabin is the fourth person in the world to reach the tallest peak on each of the seven continents. His passion for mountain climbing directed him to his professional career in eye care. After summiting Mt. Everest, on one of his expeditions, he came across a Dutch team performing cataract surgery on a woman who had been needlessly blind for three years. It was then he understood his life calling.
Tabin graduated from Yale University and then earned an MA in Philosophy at Oxford University on a Marshall Scholarship. From there, he took his interest in moral philosophy and health care delivery to Harvard Medical School where he earned his MD in 1985. After completing an ophthalmology residency at Brown University and a fellowship in corneal surgery in Melbourne, Australia, Dr. Tabin returned to Nepal to work with Dr. Sanduk Ruit.
Tabin and Nepalese eye surgeon Dr. Sanduk Ruit established the Himalayan Cataract Project in 1995 – with a vow to work to eliminate all preventable and treatable blindness from the Himalayan region in their lifetime, a goal, in Tabin’s words, “more audacious than setting out to make the first assent of the East Face of Mount Everest.” Dr. Ruit, whom the Associated Press heralded as the “god of sight” to the world’s poor, and Tabin have proven that hospital quality standards can be applied in impoverished areas devoid of electricity and clean water. Their successful approach to restoring sight and dogged perseverance has made possible what 20 years ago seemed impossible.
The Himalayan Cataract Project has since expanded beyond the Himalayas to encompass Sub-Saharan Africa as well. Dr.Tabin spends a considerable part of the year working abroad throughout the Himalayas and Sub-Saharan Africa. At Stanford his practice focus encompasses surgery and treatment of diseases of the anterior and external eye including cataract and corneal surgery. -
Daniel SW Ting
Adjunct Clinical Associate Professor, Ophthalmology
BioAssoc Prof Daniel Ting is a senior consultant vitreo-retinal surgeon working in the Singapore National Eye Center (SNEC), an Associate Professor with Duke-NUS Medical School and an Adjunct Clinical Associate Professor and an Innovation Mentor at Stanford University. He is also the Director of Singapore Health Service (SingHealth) AI Office, SNEC Chief Data and Digital Officer, and the Head of AI and Digital Innovation in Singapore Eye Research Institute (SERI). In 2017, Dr Ting was US-ASEAN Fulbright Scholar visiting the Johns Hopkins University Fulbright Scholar to share his expertise in AI and big data in medicine. In addition to that, his research focus span across not only on the technical aspect on machine learning, deep learning, large language models, explainable AI, privacy preserving technologies, but also safe, responsible and ethical clinical AI applications. He is also involved in several international consensus reporting guidelines such as STARD-AI, QUADAS-AI and DECIDE-AI.
To date, Daniel has published >250 publications on peer reviewed, book chapters, educational articles and conference abstracts. Of those, 45 were published in high impact journals (IF >10) such as JAMA, NEJM, Lancet, Nature Medicine, Nature Biomedical Engineering, Lancet Digital Health, Progress in Retinal and Eye Research, Diabetes Care, Nature Digital Medicine, Ophthalmology and etc. As of Aug 2024 (Google Scholar), his current H index: 61, i-10 index: 172 with total citations of >20,000. Dr Ting has received a total of 100M research grants, in which 20 M as a principal investigator, and 80M as co-investigators on AI and digital innovation related projects in health.
Dr Ting serves in several leadership positions at the different AI and eye societies, including the American Academy of Ophthalmology AI and Retina Ophthalmology Technology Assessment committees, and he also chairs the AI and Digital Innovation Standing Committee for the Asia-Pacific Academy of Ophthalmology and Asia-Pacific Vitreo-Retinal Society. He also serves in numerous advisory and editorial boards in the top-tiered digital and medical journals, including Lancet Digital Health, Frontiers in Medicine, Frontiers in Digital Health and Asia-Pacific Journal of Ophthalmology; Section Editor in British Journal of Ophthalmology and Editorial Board Member in Ophthalmology, Ophthalmology Retina, Ophthalmology Science, British Journal of Ophthalmology, Asia-Pacific Journal of Ophthalmology and Retina.
For the accomplishment, Dr Ting was recognized by many top-tiered international AI and ophthalmology societies in winning many prestigious scientific awards, including Tatler Asia Gen T Award (2021), Singapore National Clinician Scientist Award (2021), Asia-Pacific Academy Ophthalmology (APAO) Nakajima Award (2021), Asia-Pacific Vitreo-Retinal Society (APVRS) Ian Constable Award (2021), MICCAI OMIA Prestigious Achievement Award (2020), ARVO Bert Glaser Award for Innovative Research in Retina (2020), USA Macula Society Evangelos Gragoudas Award (2019), APAO Young Ophthalmologist’s Award (2018) and APTOS Young Innovator Award (2017).
In 2022, 2023 and 2024, he is included in the World’s Top 100 Ophthalmology Power list by the Ophthalmologists; and the World’s Top 2% Scientists by the Stanford University world ranking. In 2021, 2022 and 2023, he was consistently ranked top 3 in the deep learning domain over the past decades (2010 – 2023) by the ExpertScape. In 2024, he won the Singapore National Academy of Medicine Young Scientist Award, and also ranked the Top 100 AI Thought Leaders Worldwide with Fei Fei Li, Yan LeCun, Jensen Huang and many others by H20.ai. -
Douglas Vollrath
Professor of Genetics and, by courtesy, of Ophthalmology
Current Research and Scholarly InterestsThe Vollrath lab works to uncover molecular mechanisms relevant to the health and pathology of the outer retina. We study metabolic and other cellular interactions between the glial-like retinal pigment epithelium (RPE) and adjacent photoreceptors, with the goals of understanding the pathogenesis of photoreceptor degenerative diseases such as age-related macular degeneration and retinitis pigmentosa, and developing therapies.
-
Karen Wai, MD
Clinical Assistant Professor, Ophthalmology
BioDr. Wai is a board-certified ophthalmologist and fellowship-trained vitreoretinal surgeon with Stanford Health Care Byers Eye Institute. She is also a clinical assistant professor of ophthalmology in the Department of Ophthalmology at Stanford University School of Medicine.
Dr. Wai is a retina specialist who diagnoses and treats retinal and macular diseases, including age-related macular degeneration, diabetic retinopathy, retinal vascular occlusions (blockages), and retinal tears/detachments. The retina is a tissue layer in the back of the eye. It converts light into signals that the brain then interprets as images. The macula is the part of the retina responsible for central (straight ahead) vision. Diseases of the retina and macula can cause low vision and vision loss.
Dr. Wai’s research interests include working with data from electronic health record databases to improve patient outcomes. She has researched morbidity and mortality (illness and death) rates in patients with retinal vein occlusions and retinal artery occlusions. A retinal vein occlusion is a blocked vein to the retina that can cause vision loss. A retinal artery occlusion is when an artery to the retina is blocked, which is also sometimes referred to as eye stroke. Dr. Wai has also examined the effects of systemic medications on the retina. She has won several ophthalmology awards, including the Heed Fellowship and Harvard Medical School’s Excellence in Clinical Instruction Resident Award.
Dr. Wai has published in more than 40 peer-reviewed journals, including Ophthalmology, American Journal of Ophthalmology, and JAMA Ophthalmology. She has presented research at meetings and conferences around the United States.
Dr. Wai is a member of the American Board of Ophthalmology. -
Brian A. Wandell
Isaac and Madeline Stein Family Professor and Professor, by courtesy, of Electrical Engineering, of Ophthalmology and of Education
Current Research and Scholarly InterestsModels and measures of the human visual system. The brain pathways essential for reading development. Diffusion tensor imaging, functional magnetic resonance imaging and computational modeling of visual perception and brain processes. Image systems simulations of optics and sensors and image processing. Data and computation management for reproducible research.
-
Sophia Y. Wang, MD, MS
Assistant Professor of Ophthalmology
Current Research and Scholarly InterestsI use and integrate a wide variety of data sources in my research, spanning both structured and unstructured forms, including national survey datasets, health insurance claims data, patient generated online text, surgical video, and electronic health records. I investigate outcomes of treatments for glaucoma and cataract, as well as other areas of ophthalmology. My focus is on developing artificial intelligence methods to predict ophthalmology outcomes, while ensuring fairness.
-
Sui Wang, PhD
Assistant Professor of Ophthalmology
Current Research and Scholarly InterestsOur research focuses on unraveling the molecular mechanisms underlying retinal development and diseases. We employ genetic and genomic tools to explore how various retinal cell types, including neurons, glia, and the vasculature, respond to developmental cues and disease insults at the epigenomic and transcriptional levels. In addition, we investigate their interactions and collective contributions to maintain retinal integrity.
1. Investigating retinal development:
We utilize genetic tools and methods such as in vivo plasmid electroporation and CRISPR to dissect the roles of cis-regulatory elements and transcription factors in controlling retinal development.
2. Understanding diabetes-induced cell-type-specific responses in the retina:
Diabetes triggers a range of multicellular responses in the retina, such as vascular lesions, glial dysfunction, and neurodegeneration, all of which contribute to retinopathy. We delve into the detailed molecular mechanisms underlying these diabetes-induced cell-type-specific responses and the pathogenesis of diabetic retinopathy.
3. Developing molecular tools for labeling and manipulation of specific cell types in vivo:
Cis-regulatory elements, particularly enhancers, play pivotal roles in directing tissue- and cell-type-specific expression. Our interest lies in identifying enhancers that can drive cell type-specific expression in the retina and brain. We incorporate these enhancers into plasmid or AAV-based delivery systems, enabling precise labeling and manipulation of specific cell types in vivo. -
Albert Y. Wu, MD, PhD, FACS
Assistant Professor of Ophthalmology
Current Research and Scholarly InterestsMy translational research focuses on using autologous stem cells to recreate a patient’s ocular tissues for potential transplantation. We are generating tissue from induced pluripotent stem cells to treat limbal stem cell deficiency in patients who are bilaterally blind. By applying my background in molecular and cellular biology, stem cell biology, oculoplastic surgery, I hope to make regenerative medicine a reality for those suffering from orbital and ocular disease.
-
Charles Yu MD
Assistant Professor of Ophthalmology
Current Research and Scholarly InterestsCorneal opacity is a leading cause of blindness. Cornea transplantation is at high risk of rejection when there is pre-existing vascularization of the cornea and in pediatric patients. Cornea transplant shortage remains a worldwide problem with millions on waitlists. Our laboratory is developing multiple strategies for treatment of corneal blindness. We are testing advanced materials and designs for keratoprostheses with the goal of reducing complications and easing surgical implantation. We are also developing intraocular electronic display prostheses for bypassing cornea opacity, a novel strategy that could allow for high quality vision without corneal clarity.
